P976: REAL-WORLD OUTCOMES OF PATIENTS WITH PENTA-EXPOSED MULTIPLE MYELOMA WHO WERE TREATED WITH SELINEXOR AND DEXAMETHASONE: KOREAN MULTICENTER RETROSPECTIVE ANALYSIS

P976: REAL-WORLD OUTCOMES OF PATIENTS WITH PENTA-EXPOSED MULTIPLE MYELOMA WHO WERE TREATED WITH SELINEXOR AND DEXAMETHASONE: KOREAN MULTICENTER RETROSPECTIVE ANALYSIS

Bibliographic Details
Main Authors:	Jun Ho Yi, Sung-Soo Park, Chang-Ki Min, Hyeon-Seok Eom, Youngil Koh, Ja Min Byun, Sung-Soo Yoon, Jae Hoon Lee, Sung-Hoon Jung, Je-Jung Lee, Sang Eun Yoon, Kihyun Kim
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000970808.29064.21

Similar Items

The Novel Inhibitory Effect of YM976 on Adipocyte Differentiation
by: Hee Jung Kim, et al.
Published: (2023-01-01)

Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
by: Cristina Gasparetto, et al.
Published: (2021-02-01)

Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: Results of the multicenter KMMWP2201 study
by: Ji Hyun Lee, et al.
Published: (2024-06-01)

Evaluation of the R2‐ISS in real‐world patients with newly diagnosed multiple myeloma: A nationwide cohort study by the Korean Multiple Myeloma Working Party (KMM 2202)
by: Hyungwoo Cho, et al.
Published: (2024-01-01)

Revealing Genomic Profile That Underlies Tropism of Myeloma Cells Using Whole Exome Sequencing
by: Youngil Koh, et al.
Published: (2015-01-01)

Comparative analysis of single versus tandem autologous stem cell transplantation in patients with multiple myeloma in Korea: the KMM2102 study
by: Jongheon Jung, et al.
Published: (2024-10-01)

Busulfan and thiotepa as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-1801 study)
by: Ga-Young Song, et al.
Published: (2022-08-01)

P976: BENDAMUSTINE-POMALIDOMIDE-DEXAMETHASONE (BPD) FOR RELAPSED AND/OR REFRACTOR MULTIPLE MYELOMA WITH EXTRAMEDULLARY DISEASE
by: Z. Yuping, et al.
Published: (2022-06-01)

Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma with extramedullary disease
by: Junjing Yin, et al.
Published: (2024-11-01)

Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma
by: Michael Dolph, et al.
Published: (2021-08-01)

Selinexor in combination with dexamethasone with or without bortezomib in heavily pretreated multiple myeloma: A case series
by: Nini Aung, et al.
Published: (2024-10-01)

Selinexor in relapsed/refractory multiple myeloma
by: Joshua Richter, et al.
Published: (2020-06-01)

Real-world outcomes of maintenance therapy post-autologous stem cell transplantation in newly diagnosed multiple myeloma
by: Ka-Won Kang, et al.
Published: (2025-02-01)

Validation of the revised diagnostic criteria for primary plasma cell leukemia by the Korean Multiple Myeloma Working Party
by: Sung-Hoon Jung, et al.
Published: (2022-11-01)

Treatment of multiple myeloma with selinexor: a review
by: Qianlei Huang, et al.
Published: (2024-01-01)

PB2138: ORAL REGIMEN SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): SAFETY ASSESSMENT AND OPTIMIZATION
by: Juan Du, et al.
Published: (2023-08-01)

Distinct predictive impact of FISH abnormality in proteasome inhibitors and immunomodulatory agents response: redefining high‐risk multiple myeloma in Asian patients
by: Ja Min Byun, et al.
Published: (2018-03-01)

Selinexor: Targeting a novel pathway in multiple myeloma
by: Clifton C. Mo, et al.
Published: (2023-08-01)

Overall survival with oral selinexor plus low‐dose dexamethasone versus real‐world therapy in triple‐class‐refractory multiple myeloma
by: Paul G. Richardson, et al.
Published: (2021-02-01)

P917: SELINEXOR, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: UPDATED RESULTS OF BOSTON TRIAL BY PRIOR THERAPIES
by: Maria-Victoria Mateos, et al.
Published: (2023-08-01)

Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
by: Darrell White, et al.
Published: (2024-05-01)

Mobilization of hematopoietic stem cells with lenograstim in multiple myeloma patients: Prospective multicenter observational study (KMM122)
by: Eun Hee Jung, et al.
Published: (2023-04-01)

P1157: PHASE II STUDY OF GLOFITAMAB, POSELTINIB AND LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE B CELL LYMPHOMAS
by: Ja Min Byun, et al.
Published: (2023-08-01)

P888: MATCHED-ADJUSTED INDIRECT COMPARISON OF TALQUETAMAB VS SELINEXOR-DEXAMETHASONE AND VS BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: Ajai Chari, et al.
Published: (2023-08-01)

Adoptive NK Cell Therapy - a Beacon of Hope in Multiple Myeloma Treatment
by: Son Hai Vu, et al.
Published: (2023-11-01)

US Budget Impact Model for Selinexor in Relapsed or Refractory Multiple Myeloma
by: Bassali J, et al.
Published: (2020-06-01)

PB1859: DNMT3A MUTATION PATTERNS AND CLINICAL FEATURES IN KOREAN ACUTE MYELOID LEUKEMIA PATIENTS
by: Eunyoung Lee, et al.
Published: (2023-08-01)

Effects of Somatic Mutations Are Associated with SNP in the Progression of Individual Acute Myeloid Leukemia Patient: The Two-Hit Theory Explains Inherited Predisposition to Pathogenesis
by: Soyoung Park, et al.
Published: (2013-03-01)

Effects of Experimental Parameters on Condensation Heat Transfer in Plate Fin Heat Exchanger
by: Sung-Hoon Seol, et al.
Published: (2021-11-01)

Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study
by: Verónica González-Calle, et al.
Published: (2024-02-01)

P886: EFFICACY, SURVIVAL AND SAFETY OF SELINEXOR, BORTEZOMIB AND DEXAMETHASONE (SVD) IN PATIENTS WITH LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA: SUBGROUP DATA FROM THE BOSTON TRIAL
by: Maria-Victoria Mateos, et al.
Published: (2023-08-01)

PB2014: TECLISTAMAB VS SELINEXOR-DEXAMETHASONE IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MATCHING-ADJUSTED INDIRECT COMPARISON
by: L. Rosinol, et al.
Published: (2022-06-01)

Systematic analysis of Mendelian disease-associated gene variants reveals new classes of cancer-predisposing genes
by: Seulki Song, et al.
Published: (2023-12-01)

PB2096: SELINEXOR COMBINED REGIMEN FOR MULTIPLE MYELOMA WITH EXTRAMEDULLARY DISEASE(EMD)
by: Yuping Zhong, et al.
Published: (2023-08-01)

Dexamethasone does not prevent hydrocephalus after severe intraventricular hemorrhage in newborn rats.
by: Jang Hoon Lee, et al.
Published: (2018-01-01)

Case report: Light-chain amyloidosis responsive to selinexor in combination with daratumumab and dexamethasone (SDd) therapy
by: Xiaolu Long, et al.
Published: (2024-05-01)

Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a Model of Murine Myeloma
by: Manh-Cuong Vo, et al.
Published: (2018-06-01)

P982: EFFICACY AND SAFETY OF 40 MG VS 60 MG OF ONCE WEEKLY SELINEXOR IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)
by: Darrell White, et al.
Published: (2023-08-01)

P974: INTERIM ANALYSIS OF THE LAUNCH STUDY-A MULTICENTER, OPEN-LABEL STUDY OF SELINEXOR, DEXAMETHASONE PLUS CHEMOTHERAPY DRUGS IN RELAPSED/ REFRACTORY MULTIPLE MYELOMA
by: Chunyan Sun, et al.
Published: (2023-08-01)

P878: SELINEXOR IN COMBINATION WITH DARATUMUMAB-BORTEZOMIB AND DEXAMETHASONE FOR THE TREATMENT OF RELAPSE OR REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS OF THE PHASE 2, MULTICENTER GEM-SELIBORDARA STUDY
by: Veronica Gonzalez-Calle, et al.
Published: (2023-08-01)